Efficacy and safety of co-trimoxazole in device-related bone and joint infections: a CRIOGO multicentre case–control study
Co-trimoxazole appears to be an effective alternative for the treatment of BJI, even when it occurs on a device, but the safety profile requires close monitoring of adverse effects.
Authors
- David Boutoille (ORCID: https://orcid.org/0000-0001-9722-2029)
- Stéphane Corvec (ORCID: https://orcid.org/0000-0003-3176-8111)
- Géraldine Bart (ORCID: https://orcid.org/0000-0001-5981-5026)
- Louise Ruffier d’Epenoux (ORCID: https://orcid.org/0009-0009-0461-8848)
- Séverine Ansart (ORCID: https://orcid.org/0000-0002-4901-3975)
- Colin Deschanvres (ORCID: https://orcid.org/0000-0002-1133-5207)
- Amandine Le Bourgeois (ORCID: https://orcid.org/0000-0002-0370-7867)
- R. Lecomte (ORCID: https://orcid.org/0000-0003-2144-9221)
- Rafaël Mahieu
- Nathalie Asseray (ORCID: https://orcid.org/0000-0002-7223-7600)
- G. Le Moal
Institutions
- Inserm (FR)
- Military Hospital (PK)
- Hotel Dieu Hospital (CA)
- Centre Hospitalier Universitaire de Nantes (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Centre Hospitalier Régional Universitaire de Brest (FR)
- Hôtel-Dieu de Paris (FR)
- Hôpital d'instruction des Armées Percy (FR)
- Nantes Université (FR)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1093/jac/dkae328
- Citations
- 3
- Primary Topic
- Orthopedic Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.72